Published in Atherosclerosis on July 21, 2010
Receptor for AGE (RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications. Ann N Y Acad Sci (2011) 1.60
Role of advanced glycation end products in cellular signaling. Redox Biol (2014) 1.36
RAGE expression in human T cells: a link between environmental factors and adaptive immune responses. PLoS One (2012) 1.09
Manufactured and airborne nanoparticle cardiopulmonary interactions: a review of mechanisms and the possible contribution of mast cells. Inhal Toxicol (2012) 1.02
Phosphatidylserine receptors: enhancers of enveloped virus entry and infection. Virology (2014) 0.93
RAGE and tobacco smoke: insights into modeling chronic obstructive pulmonary disease. Front Physiol (2012) 0.90
An interactive association of advanced glycation end-product receptor gene four common polymorphisms with coronary artery disease in northeastern Han Chinese. PLoS One (2013) 0.83
A prospective cohort study of periodontal disease measures and cardiovascular disease markers in HIV-infected adults. AIDS Res Hum Retroviruses (2011) 0.83
Diabetes and oral disease: implications for health professionals. Ann N Y Acad Sci (2012) 0.81
Alpha-mangostin attenuation of hyperglycemia-induced ocular hypoperfusion and blood retinal barrier leakage in the early stage of type 2 diabetes rats. Biomed Res Int (2015) 0.78
The GroEL protein of Porphyromonas gingivalis regulates atherogenic phenomena in endothelial cells mediated by upregulating toll-like receptor 4 expression. Am J Transl Res (2016) 0.77
Effects of age-related shifts in cellular function and local microenvironment upon the innate immune response to implants. Semin Immunol (2017) 0.75
Periodontal diseases. Lancet (2005) 10.13
Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med (1998) 5.54
Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem (1992) 3.64
Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice. J Clin Invest (2008) 3.11
Innate immune recognition of invasive bacteria accelerates atherosclerosis in apolipoprotein E-deficient mice. Circulation (2004) 2.46
Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation (2002) 2.18
Oral infection with a periodontal pathogen accelerates early atherosclerosis in apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol (2003) 2.17
Oxygen deprivation triggers upregulation of early growth response-1 by the receptor for advanced glycation end products. Circ Res (2008) 1.94
A simple method of isolating mouse aortic endothelial cells. J Atheroscler Thromb (2005) 1.88
Invasion of human coronary artery cells by periodontal pathogens. Infect Immun (1999) 1.84
Blockade of RAGE suppresses periodontitis-associated bone loss in diabetic mice. J Clin Invest (2000) 1.82
Bacteraemia following periodontal procedures. J Clin Periodontol (2005) 1.61
The periodontal pathogen Porphyromonas gingivalis cleaves apoB-100 and increases the expression of apoM in LDL in whole blood leading to cell proliferation. J Intern Med (2008) 1.51
The association between periodontal diseases and cardiovascular diseases: a state-of-the-science review. Ann Periodontol (2001) 1.42
A role for advanced glycation end products in diminished bone healing in type 1 diabetes. Diabetes (2003) 1.34
The role of AGEs in cardiovascular disease. Curr Pharm Des (2008) 1.29
Porphyromonas gingivalis bacteremia induces coronary and aortic atherosclerosis in normocholesterolemic and hypercholesterolemic pigs. Arterioscler Thromb Vasc Biol (2005) 1.26
Receptor for advanced glycation end products: fundamental roles in the inflammatory response: winding the way to the pathogenesis of endothelial dysfunction and atherosclerosis. Ann N Y Acad Sci (2008) 1.17
Synergistic action of advanced glycation end products and endogenous nitric oxide leads to neuronal apoptosis in vitro: a new insight into selective nitrergic neuropathy in diabetes. Diabetologia (2003) 1.17
Importance of TLR2 in early innate immune response to acute pulmonary infection with Porphyromonas gingivalis in mice. J Immunol (2008) 1.16
Potential infectious etiologies of atherosclerosis: a multifactorial perspective. Emerg Infect Dis (2001) 1.11
RAGE on the Toll Road? Cell Mol Immunol (2006) 1.10
Role for periodontal bacteria in cardiovascular diseases. Ann Periodontol (2001) 1.04
Infection with a periodontal pathogen increases mononuclear cell adhesion to human aortic endothelial cells. Atherosclerosis (2006) 1.03
Infection with a periodontal pathogen induces procoagulant effects in human aortic endothelial cells. J Thromb Haemost (2006) 0.92
Induction of monocyte chemoattractant protein-1 by Porphyromonas gingivalis in human endothelial cells. FEMS Immunol Med Microbiol (2002) 0.83
Porphyromonas gingivalis infection and prothrombotic effects in human aortic smooth muscle cells. Thromb Res (2008) 0.83
Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation (2006) 5.31
Periodontal disease and atherosclerotic vascular disease: does the evidence support an independent association?: a scientific statement from the American Heart Association. Circulation (2012) 5.25
RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med (2003) 5.14
Treatment of periodontal disease and the risk of preterm birth. N Engl J Med (2006) 4.81
Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res (2004) 4.00
RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation (2002) 3.93
Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest (2004) 3.89
Periodontal microbiota and carotid intima-media thickness: the Oral Infections and Vascular Disease Epidemiology Study (INVEST). Circulation (2005) 3.25
Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice. J Clin Invest (2008) 3.11
Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology (2005) 2.74
Relationship between periodontal disease, tooth loss, and carotid artery plaque: the Oral Infections and Vascular Disease Epidemiology Study (INVEST). Stroke (2003) 2.45
RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol (2003) 2.43
Examining the safety of dental treatment in pregnant women. J Am Dent Assoc (2008) 2.41
Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest (2003) 2.40
Delays in breast cancer diagnosis and treatment by racial/ethnic group. Arch Intern Med (2006) 2.32
Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ Res (2003) 2.25
Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. Nat Rev Drug Discov (2009) 2.24
Hyperglycemia promotes myelopoiesis and impairs the resolution of atherosclerosis. Cell Metab (2013) 2.20
Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clin Cancer Res (2007) 2.20
The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature. Circ Res (2010) 2.19
Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation (2002) 2.18
Diabetes mellitus and periodontitis: a tale of two common interrelated diseases. Nat Rev Endocrinol (2011) 2.17
Oral infection with a periodontal pathogen accelerates early atherosclerosis in apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol (2003) 2.17
The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation (2003) 2.14
Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications. Nat Clin Pract Endocrinol Metab (2008) 2.13
Analytical epidemiology of periodontitis. J Clin Periodontol (2005) 2.10
RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. EMBO J (2004) 2.08
S100P stimulates cell proliferation and survival via receptor for activated glycation end products (RAGE). J Biol Chem (2003) 2.05
Use of traditional and complementary/alternative medicine (TCAM) in children with cancer in Guatemala. Pediatr Blood Cancer (2013) 1.98
Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42. J Biol Chem (2008) 1.97
Identification, classification, and expression of RAGE gene splice variants. FASEB J (2007) 1.96
Oxygen deprivation triggers upregulation of early growth response-1 by the receptor for advanced glycation end products. Circ Res (2008) 1.94
The relationship between oral health and diabetes mellitus. J Am Dent Assoc (2008) 1.88
RAGE: therapeutic target and biomarker of the inflammatory response--the evidence mounts. J Leukoc Biol (2009) 1.84
Advanced glycation end product recognition by the receptor for AGEs. Structure (2011) 1.84
Clinical and serologic markers of periodontal infection and chronic kidney disease. J Periodontol (2008) 1.80
Blockade of receptor for advanced glycation end product (RAGE) attenuates ischemia and reperfusion injury to the liver in mice. Hepatology (2004) 1.77
Protein glycation: a firm link to endothelial cell dysfunction. Circ Res (2004) 1.76
RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes. Atherosclerosis (2005) 1.67
Receptor for advanced glycation end product-dependent activation of p38 mitogen-activated protein kinase contributes to amyloid-beta-mediated cortical synaptic dysfunction. J Neurosci (2008) 1.67
Suppression of experimental autoimmune encephalomyelitis by selective blockade of encephalitogenic T-cell infiltration of the central nervous system. Nat Med (2003) 1.62
On the primary care frontlines: the role of the general practitioner in smoking-cessation activities and diabetes management. J Am Dent Assoc (2005) 1.61
Receptor for AGE (RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications. Ann N Y Acad Sci (2011) 1.60
Anti-receptor for advanced glycation end products therapies as novel treatment for abdominal aortic aneurysm. Ann Surg (2009) 1.60
Peripheral venous congestion causes inflammation, neurohormonal, and endothelial cell activation. Eur Heart J (2013) 1.60
Development of receptor for advanced glycation end products-directed imaging of atherosclerotic plaque in a murine model of spontaneous atherosclerosis. Circ Cardiovasc Imaging (2008) 1.58
Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings. Adv Drug Deliv Rev (2002) 1.56
The RAGE axis in early diabetic retinopathy. Invest Ophthalmol Vis Sci (2005) 1.55
Blockade of late stages of autoimmune diabetes by inhibition of the receptor for advanced glycation end products. J Immunol (2004) 1.55
RAGE: a novel biological and genetic marker for vascular disease. Clin Sci (Lond) (2009) 1.52
Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory response. J Mol Med (Berl) (2009) 1.51
Receptor for advanced-glycation end products: key modulator of myocardial ischemic injury. Circulation (2006) 1.48
The relationship of periodontal disease to diseases and disorders at distant sites: communication to health care professionals and patients. J Am Dent Assoc (2008) 1.48
Retracted Receptor for advanced glycation end products (RAGEs) and experimental diabetic neuropathy. Diabetes (2007) 1.44
RAGE activation by S100P in colon cancer stimulates growth, migration, and cell signaling pathways. Dis Colon Rectum (2007) 1.44
Periodontitis and atherosclerotic vascular disease: what we know and why it is important. J Am Dent Assoc (2012) 1.43
Epidemiologic patterns of chronic and aggressive periodontitis. Periodontol 2000 (2010) 1.42
RAGE ligation affects T cell activation and controls T cell differentiation. J Immunol (2008) 1.41
Imaging of receptors for advanced glycation end products in experimental myocardial ischemia and reperfusion injury. JACC Cardiovasc Imaging (2012) 1.40
Inflammation-induced chondrocyte hypertrophy is driven by receptor for advanced glycation end products. J Immunol (2005) 1.39
Biventricular pacing improves left ventricular function by 2-D strain in right ventricular failure. J Surg Res (2012) 1.39
RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/memory in a mouse model of Alzheimer's disease. FASEB J (2009) 1.39
RAGE: a potential target for Abeta-mediated cellular perturbation in Alzheimer's disease. Curr Mol Med (2007) 1.38
Receptor for AGE (RAGE) mediates neointimal formation in response to arterial injury. Circulation (2003) 1.38
Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol (2006) 1.38
Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes. Ageing Res Rev (2002) 1.37
Receptor for advanced glycation end products (RAGE) in a dash to the rescue: inflammatory signals gone awry in the primal response to stress. J Leukoc Biol (2007) 1.36
Soluble receptor for advanced glycation end products: a new biomarker in diagnosis and prognosis of chronic inflammatory diseases. Rheumatology (Oxford) (2009) 1.36
Arguing for the motion: yes, RAGE is a receptor for advanced glycation endproducts. Mol Nutr Food Res (2007) 1.35
RAGE modulates peripheral nerve regeneration via recruitment of both inflammatory and axonal outgrowth pathways. FASEB J (2004) 1.35
RAGE limits regeneration after massive liver injury by coordinated suppression of TNF-alpha and NF-kappaB. J Exp Med (2005) 1.35
The receptor for advanced glycation endproducts (RAGE) and cardiovascular disease. Expert Rev Mol Med (2009) 1.35
AGE/RAGE produces endothelial dysfunction in coronary arterioles in type 2 diabetic mice. Am J Physiol Heart Circ Physiol (2008) 1.32
Deletion of the receptor for advanced glycation end products reduces glomerulosclerosis and preserves renal function in the diabetic OVE26 mouse. Diabetes (2010) 1.32
Mechanisms for the induction of HNE- MDA- and AGE-adducts, RAGE and VEGF in retinal pigment epithelial cells. Exp Eye Res (2005) 1.31
Transcriptomes in healthy and diseased gingival tissues. J Periodontol (2008) 1.30
Receptor for advanced glycation endproducts (RAGE) and vascular inflammation: insights into the pathogenesis of macrovascular complications in diabetes. Curr Atheroscler Rep (2002) 1.30
Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy. J Am Soc Nephrol (2003) 1.30